Mostrar el registro sencillo del ítem

dc.contributor.authorCasabonne, Delphine
dc.contributor.authorBenavente, Yolanda
dc.contributor.authorRobles, Claudia
dc.contributor.authorCostas, Laura
dc.contributor.authorAlonso, Esther
dc.contributor.authorGonzalez-Barca, Eva
dc.contributor.authorTardón, Adonina
dc.contributor.authorDierssen-Sotos, Trinidad
dc.contributor.authorVázquez, Eva Gimeno
dc.contributor.authorAymerich, Marta
dc.contributor.authorCampo, Elias
dc.contributor.authorCastaño-Vinyals, Gemma 
dc.contributor.authorAragones, Nuria 
dc.contributor.authorPollan-Santamaria, Marina 
dc.contributor.authorKogevinas, Manolis
dc.contributor.authorJuwana, Hedy
dc.contributor.authorMiddeldorp, Jaap
dc.contributor.authorde Sanjose, Silvia
dc.date.accessioned2019-01-31T09:57:50Z
dc.date.available2019-01-31T09:57:50Z
dc.date.issued2015-02-09
dc.identifier.citationInfect Agent Cancer. 2015 Feb 9;10:5.es_ES
dc.identifier.issn1750-9378es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/7038
dc.description.abstractBACKGROUND: Epstein-Barr virus (EBV)-related malignancies harbour distinct serological responses to EBV antigens. We hypothesized that EBV serological patterns can be useful to identify different stages of chronic lymphocytic leukemia. METHODS: Information on 150 cases with chronic lymphocytic leukemia and 157 frequency-matched (by age, sex and region) population-based controls from a Spanish multicentre case-control study was obtained. EBV immunoglobulin G serostatus was evaluated through a peptide-based ELISA and further by immunoblot analysis to EBV early antigens (EA), nuclear antigen (EBNA1), VCA-p18, VCA-p40 and Zebra. Two independent individuals categorized the serological patterns of the western blot analysis. Patients with very high response and diversity in EBV-specific polypeptides, in particular with clear responses to EA-associated proteins, were categorized as having an abnormal reactive pattern (ab_EBV). Adjusted odds ratios (OR) and 95% confidence interval (CI) were estimated using logistic regression models. RESULTS: Almost all subjects were EBV-IgG positive (>95% of cases and controls) whereas ab_EBV patterns were detected in 23% of cases (N = 34) and 11% of controls (N = 17; OR: 2.44, 95% CI, 1.29 to 4.62; P = 0.006), particularly in intermediate/high risk patients. Although based on small numbers, the association was modified by smoking with a gradual reduction of ab_EBV-related OR for all Rai stages from never smokers to current smokers. CONCLUSIONS: Highly distinct EBV antibody diversity patterns revealed by immunoblot analysis were detected in cases compared to controls, detectable at very early stages of the disease and particularly among non smokers. This study provides further evidence of an abnormal immunological response against EBV in patients with chronic lymphocytic leukemia.es_ES
dc.description.sponsorshipThis work was supported by the “Acción Transversal del Cancer”, approved on the Spanish Ministry Council on the 11th October 2007, by the Instituto de Salud Carlos III (Spanish Government) (grants PI08/1770, PI08/0533, PI08/1359, PS09/00773-Cantabria, PI11/01810, PI11/02213, RCESP C03/09, RTICESP C03/10, RTIC RD06/0020/0095, RTIC RD12/0036/0056, Rio Hortega CM13/00232, SV-09-CLINIC-1 and CIBERESP), by the Fundación Marques de Valdecilla (API 10/09), by Obra Social CAJASTUR (SV-CAJASTUR-1), by the Recercaixa (2010ACUP 00310), by the Spanish Association Against Cancer (AECC) Scientific Foundation and by the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR)–Generalitat de Catalunya (Catalonian Government) (grants AGAUR 2009SGR1026, 2014SGR756 and 2009SGR1465). The ICGC CLL-Genome Project is funded by Spanish Ministerio de Economía y Competitividad (MINECO) through the Instituto de Salud Carlos III (ISCIII) and Red Temática de Investigación del Cáncer (RTIC RD12/0036/0036) del ISCIII. Sample collection and storage was partially supported by the Instituto de Salud Carlos III FEDER (RD09/0076/00036), Xarxa de Bancs de Tumors de Catalunya sponsored by Pla Director d’Oncologia de Catalunya (XBTC).es_ES
dc.language.isoenges_ES
dc.publisherBioMed Central (BMC) es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectCase-controles_ES
dc.subjectChronic lymphocytic leukemiaes_ES
dc.subjectEpstein-Barr viruses_ES
dc.subjectSerologyes_ES
dc.subjectSmokinges_ES
dc.titleAberrant Epstein-Barr virus antibody patterns and chronic lymphocytic leukemia in a Spanish multicentric case-control studyes_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID25972916es_ES
dc.format.volume10es_ES
dc.format.number1es_ES
dc.format.page5es_ES
dc.identifier.doi10.1186/1750-9378-10-5es_ES
dc.contributor.funderInstituto de Investigación Marqués de Valdecilla 
dc.contributor.funderFundación Cajastur 
dc.contributor.funderAsociación Española Contra el Cáncer 
dc.contributor.funderInstituto de Salud Carlos III 
dc.contributor.funderFundación La Caixa 
dc.contributor.funderGovernment of Catalonia (España) 
dc.description.peerreviewedes_ES
dc.relation.publisherversionhttps://doi.org/10.1186/1750-9378-10-5es_ES
dc.identifier.journalInfectious agents and canceres_ES
dc.repisalud.centroISCIII::Centro Nacional de Epidemiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI08/1770es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI08/0533es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI08/1359es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PS09/00773-Cantabriaes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI11/01810es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI11/02213es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/RCESP C03/09es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/RTICESP C03/10es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/RTIC RD06/0020/0095es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/RTIC RD12/0036/0056es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/Rio Hortega CM13/00232es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SV-09-CLINIC-1es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/RTIC RD12/0036/0036es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/RD09/0076/00036es_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución 4.0 Internacional